title: Acquired perforating dermatosis associated with natalizumab.
authors.forename: Enric
authors.initials: E
authors.lastname: Piqué-Duran
authors.forename: Pablo
authors.initials: P
authors.lastname: Eguía
authors.forename: Odalys
authors.initials: O
authors.lastname: García-Vázquez
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001691:Biological Therapy / Q000009:adverse effects; D003879:Dermatologic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D039441:Integrin alpha4; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy; D000069442:Natalizumab; D011537:Pruritus / Q000139:chemically induced; D012871:Skin Diseases / Q000139:chemically induced* / Q000473:pathology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D000069442:Natalizumab; D039441:Integrin alpha4